Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III).
Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Nechaeva EA, Danilenko ED, Pyankov SA, Gudymo AS, Moiseeva AA, Onkhonova GS, Pyankov OV, Sleptsova ES, Lomakin NV, Vasilyeva VS, Tulikov MV, Gusarov VG, Pulin AA, Balalaeva MA, Erofeeva SB, Terpigorev SA, Rychkova OA, Petrov IM, Delian VY, Rafalskiy VV, Tyranovets SV, Gavrilova EV, Maksyutov RA. Ryzhikov AB, et al. Among authors: rafalskiy vv. Vaccines (Basel). 2023 May 18;11(5):998. doi: 10.3390/vaccines11050998. Vaccines (Basel). 2023. PMID: 37243102 Free PMC article.
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
de Mesquita YLL, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao EMH, Carvalho PEP, da Silva CHA, Cardoso R, Moura FA, Rafalskiy VV. de Mesquita YLL, et al. Among authors: rafalskiy vv. Int J Obes (Lond). 2023 Oct;47(10):883-892. doi: 10.1038/s41366-023-01337-x. Epub 2023 Jul 17. Int J Obes (Lond). 2023. PMID: 37460681 Review.
[The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases].
Stel'makh VV, Kovalenko AL, Popova VB, Uspenskiy YP, Morozov VG, Belikova TN, Rafalskiy VV, Antonova EA. Stel'makh VV, et al. Among authors: rafalskiy vv. Ter Arkh. 2021 Dec 15;93(12):1470-1476. doi: 10.26442/00403660.2021.12.201266. Ter Arkh. 2021. PMID: 36286675 Clinical Trial. Russian.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.